Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALMS 
Alumis Inc (ALMS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ALMS (1-star) is a SELL. SELL since 2 days. Simulated Profits (1.46%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $19
1 Year Target Price $19
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -52.45% | Avg. Invested days 22 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 432.91M USD | Price to earnings Ratio 0.13 | 1Y Target Price 19 |
Price to earnings Ratio 0.13 | 1Y Target Price 19 | ||
Volume (30-day avg) 6 | Beta - | 52 Weeks Range 2.76 - 13.11 | Updated Date 09/17/2025 |
52 Weeks Range 2.76 - 13.11 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 33.18 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -4532.6% |
Management Effectiveness
Return on Assets (TTM) -59.84% | Return on Equity (TTM) -66.35% |
Valuation
Trailing PE 0.13 | Forward PE - | Enterprise Value -14637504 | Price to Sales(TTM) 21.59 |
Enterprise Value -14637504 | Price to Sales(TTM) 21.59 | ||
Enterprise Value to Revenue 0.38 | Enterprise Value to EBITDA - | Shares Outstanding 96879394 | Shares Floating 71049902 |
Shares Outstanding 96879394 | Shares Floating 71049902 | ||
Percent Insiders 0.83 | Percent Institutions 81.07 |
Upturn AI SWOT
Alumis Inc
Company Overview
History and Background
Alumis, Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies for autoimmune diseases. Founded in 2021, Alumis aims to address unmet needs in autoimmune disease treatment by targeting specific disease drivers. Alumis raised $200 million in Series C funding in 2023, furthering its development of Deucravacitinib and other products.
Core Business Areas
- Drug Development: Focuses on researching, developing, and testing oral therapies for autoimmune disorders.
- Clinical Trials: Conducts clinical trials to assess the safety and efficacy of its drug candidates.
- Partnerships: Establishes partnerships to expand its research and development capabilities.
Leadership and Structure
Alumis is led by a team of experienced pharmaceutical executives and scientists. The company operates with a functional organizational structure, with departments focused on research, development, clinical operations, and commercialization.
Top Products and Market Share
Key Offerings
- Deucravacitinib: Deucravacitinib, an oral selective TYK2 inhibitor, is Alumis' lead product candidate. It's being developed for psoriasis and other autoimmune diseases. While exact market share is nascent (drug is in trial), competitors include Amgen's Otezla. Alumis acquired exclusive global rights to develop, manufacture and commercialize the investigational TYK2 inhibitor from Eli Lilly in 2023.
- A2001: An early stage compound, it is designed to deliver greater therapeutic benefit for patients with systemic lupus erythematosus (SLE) and other diseases.
Market Dynamics
Industry Overview
The autoimmune disease market is a large and growing market, driven by an aging population, increased awareness of autoimmune diseases, and advancements in treatment options. Key players include established pharmaceutical companies and emerging biotech firms.
Positioning
Alumis is positioned as an innovative biopharmaceutical company focused on developing oral therapies for autoimmune diseases. Its competitive advantage lies in its targeted approach and potentially improved safety profile compared to existing treatments.
Total Addressable Market (TAM)
The TAM for autoimmune disease therapies is estimated to be over $100 billion. Alumis is positioned to capture a significant share of this market with its innovative drug candidates.
Upturn SWOT Analysis
Strengths
- Innovative technology platform
- Experienced management team
- Strong financial backing
- Pipeline of promising drug candidates
- Selective TYK2 inhibitor approach
Weaknesses
- Reliance on successful clinical trials
- Limited commercial infrastructure
- Competition from established pharmaceutical companies
- Product pipeline still in early stages
Opportunities
- Expansion into new autoimmune disease indications
- Strategic partnerships and collaborations
- Successful commercialization of Deucravacitinib
- Acquisition of complementary technologies or companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from new therapies
- Patent expirations
- Adverse events in clinical trials
Competitors and Market Share
Key Competitors
- AMGN
- BMY
- PFE
Competitive Landscape
Alumis competes with established pharmaceutical companies in the autoimmune disease market. Its advantages include a targeted approach and potentially improved safety profile. Disadvantages include limited resources and commercial infrastructure compared to larger competitors.
Growth Trajectory and Initiatives
Historical Growth: Alumis' growth is measured by advancements in its clinical trials and expansion of its pipeline.
Future Projections: Future growth is dependent on the successful development and commercialization of its drug candidates, particularly Deucravacitinib. Analyst estimates are unavailable due to the company's private status.
Recent Initiatives: Recent initiatives include the progression of Deucravacitinib through clinical trials and expanding its research and development efforts in other autoimmune diseases. Securing Series C funding is also a key initiative.
Summary
Alumis is a clinical-stage biopharmaceutical company with a focus on oral therapies for autoimmune diseases. The company's lead product candidate, Deucravacitinib, shows promise in treating psoriasis and other autoimmune conditions. While Alumis faces competition from larger pharmaceutical companies, its innovative technology and strong financial backing position it for potential growth. Alumis will need to ensure clinical trial success to capitalize on market opportunities.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Press Releases
- Industry Reports
- Crunchbase
- SEC filings of competitors
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is based on publicly available information and analyst estimates, which may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Alumis Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2024-06-28 | President, CEO & Chairman Mr. Martin Babler Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 225 | Website https://www.alumis.com |
Full time employees 225 | Website https://www.alumis.com | ||
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company's clinical asset comprises ESK-001, an allosteric tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. It also develops interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. The company was incorporated in 2021 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.